Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abbreviated, ADME, ANDA, benchmark, bioequivalence, BLA, Book, bound, BPCA, carryforward, certify, certifying, cited, column, conflict, contrast, decree, disincentivizing, downstream, embedded, exemplified, extravasation, FDC, fulfill, FXII, FXIIKO, GLP, Hatch, HHS, ID, ingredient, inline, insert, KOMPLETE, KONFIDENT, language, launched, likewise, living, meant, metric, molecularly, myriad, NaN, NCE, NDABLA, omission, Orange, organizational, panel, Paragraph, paw, PHS, PKa, pretreatment, QD, rat, referenced, restoration, resubmission, Russia, satisfactory, sebestralstat, sebetralstat, sebetralstrat, sebetratstat, send, timeframe, tracheal, Ukraine, undergone, unfounded, upcoming, version, viii, Waxman, whistleblower, widespread
Removed:
absorbed, accumulation, acetonide, adding, Aerpio, Affordability, aflibercept, agree, Alimera, Allegro, Allergan, ascending, Avastin, baseline, bevacizumab, binding, bloodstream, Boehringer, branded, breakdown, calendar, capsule, captioned, Carbylan, cataract, central, characterization, collected, comparative, comparison, complication, concurrently, content, corrected, correlated, corticoid, corticosteroid, derived, detailed, dexamethasone, diligent, displayed, Dohme, dominated, dramatic, enabled, equal, essentially, establishment, exact, explore, Eylea, favorably, fed, fluocinolone, fraction, gap, gavage, GlaxoSmithKline, GMP, halt, Harvard, highest, home, implanted, importance, improving, infused, Ingelheim, inhaled, innovator, instilled, Institute, intraocular, invasive, investigate, Joslin, justified, laser, leaving, led, lesser, lluvien, macula, male, mandate, mandatory, methodology, mild, minimal, minimum, modality, negotiated, notified, October, Ohr, oncology, onsite, ophthalmic, ophthalmology, optimize, optimum, osmotic, outpatient, oversee, owed, Oxurion, Ozurdex, passed, peer, pharmacodynamic, pioneered, platform, poverty, preceding, President, protective, quantified, ranibizumab, recommend, reducing, Regeneron, regime, release, repealing, replace, reproductive, rest, retinopathy, Roche, roughly, SAE, School, screened, selection, served, sham, shared, showed, solution, stolen, subcutaneously, subfield, suffered, systemic, tablet, theft, threshold, tolerability, tolerated, toxicity, unfold, upfront, validate
Filing tables
Filing exhibits
KALV similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-215185, 333-217009, 333-228831, and 333-256378 on Form S-3 and Registration Statement Nos. 333-203721, 333-215184, 333-216032, 333-217008, 333-226442, 333-230279, 333-237059, 333-254178, 333-257871 and 333-263431 on Form S-8 of our report dated July 7, 2022, relating to the financial statements of KalVista Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of KalVista Pharmaceuticals, Inc. for the year ended April 30, 2022.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
July 7, 2022